51 results about "Methamphetamine" patented technology

The invention discloses application of lycium barbarum polysaccharide in preparation of a medicine for inhibiting methylamphetamine-induced nerve injury, and relates to the technical field of biological medicines. It is found and proved that lycium barbarum polysaccharide can inhibit methylamphetamine-induced nerve injury, and the effect is remarkable. From the aspect of cell survival, the survival rate of the microglial cells pretreated by the lycium barbarum polysaccharide after METH stimulation is obviously improved. In the molecular mechanism, the lycium barbarum polysaccharide can effectively lower the protein expression level of the METH-induced pyroptosis marker, the content of inflammatory factors IL-1beta and IL-18 can be reduced, and the release of lactic dehydrogenase is reduced. The result shows that the lycium barbarum polysaccharide can alleviate inflammatory response by inhibiting NLRP3 / ASC pathway mediated microglial cell pyroptosis, thereby inhibiting METH-induced nerve injury. The invention provides a new direction for developing METH neurotoxicity intervention medicines.

Disclosed in the present invention are a drug for treating or preventing methamphetamine addiction, and the use. Also disclosed is a new use of an ERK inhibitor. In the present invention, the use of an ERK inhibitor in drug addiction is studied. The inhibitory effect of GDC-0994 in the treatment of methamphetamine addiction is studied by means of methamphetamine addiction models (including a place preference model and a self-administration experiment model), and it is found that the administration of the ERK inhibitor GDC-0994 can significantly reduce the seeking and ingesting of methamphetamine in animals, that is, the ERK inhibitor GDC-0994 can antagonize methamphetamine addiction, this indicates that the inhibition of ERK by GDC-0994 can effectively treat methamphetamine addiction.

The present disclosure relates to 3,4-methylenedioxymethamphetamine (MDMA) or a pharmaceutically acceptable salt and / or solvate thereof, pharmaceutical compositions and dosage forms containing these particles, and methods of using pharmaceutical compositions and dosage forms containing these particles to treat subjects suffering from disorders of the central nervous system.

The present invention discloses a compound for treating methamphetamine addiction and cognitive impairment, its preparation method and application. The new compound NBU513-1 for treating methamphetamine addiction and cognitive impairment induced by the present invention can significantly improve the addictive behavior of mice for methamphetamine, has a therapeutic effect on the cognitive dysfunction caused by methamphetamine, and can be used to prepare a medicine for treating methamphetamine addiction and cognitive impairment induced by methamphetamine. The present invention provides a total synthesis route of compound NBU513-1. Compared with the preparation method of similar compounds in the prior art, the method of the present invention does not need to react with sodium azide, does not produce powerful explosives and highly toxic substances, has high stability and low reaction risk; the method has mild reaction conditions, simple scheme, safe and reliable production and can prepare target products with higher yields, and is suitable for industrial production.

The present invention relates to a method for realizing methamphetamine addiction identification and craving determination on the basis of machine learning. The method comprises the following steps: collecting and pre-processing high-density scalp resting-state electroencephalogram data of a subject to obtain an EEG time series; on the basis of a standard head model, performing source locating on the acquired time series data; using a pre-defined brain template to perform electroencephalogram functional connectivity analysis; using a functional connectivity network to detect the temporal correlation or phase synchronization between a plurality of brain regions; and performing real craving manifestation feature determination on the subject by means of establishing and verifying a machine learning model. The present invention also relates to a corresponding apparatus, a processor and a storage medium therefor. By means of the method, apparatus and processor for realizing methamphetamine addiction identification and craving determination on the basis of machine learning and the storage medium therefor in the present invention, accurate identification of a methamphetamine addict and a craving state thereof can be expected, thereby facilitating the assessment of a treatment effect on methamphetamine addicts, and reducing the recurrence rate.

The application belongs to the technical field of water treatment, and particularly relates to a new psychoactive substance adsorbent and application thereof. The preparation method of the adsorbent comprises the following steps: (1) mixing and reacting activated shrimp shell biomass and ferroferric oxide nano magnetic material, drying, and pyrolyzing to obtain Fe3O4@BC; (2) mixing and reacting Fe3O4@BC and ZIF-8 to obtain Fe3O4@BC@ZIF-8; and (3) mixing and reacting a eutectic solvent with Fe3O4@BC@ZIF-8 to obtain the new psychoactive substance adsorbent. The adsorbent has strong adsorption capacity for 4-methyl methcathinone, methcathinone, amphetamine, methamphetamine and ephedrine, and the adsorption efficiency can reach 98% for 4-methyl methcathinone in particular.

The invention relates to a polymeric nanomaterial that has specific affinity for MeA (methamphetamine) or AMP (amphetamine-derived synthetic drugs) and can exist at the nanoscale, as well as to the synthesis method thereof.

The present application relates to a kind of drug rapid detection method, equipment and medium based on photonic crystal image, comprising: image pre-processing, to locate the position of photonic crystal in image and cut image, so that only photonic crystal is left in the image after cutting;Extract the color feature vector of the photonic crystal, and carry out dimension reduction processing;The color feature vector after dimension reduction is converted, identified and compared based on support vector machine, and the drug identification of the to-be-measured body fluid is completed.The present application is based on the color difference of different drugs and photonic crystal after reaction, judges what kind of drug, such as amphetamine, pseudoephedrine, chloroephedrine, methylcathinone or methamphetamine, contained in the to-be-measured liquid by comparing with standard spectrum, fast, low cost, mass detection, low equipment cost.

The invention provides a method for colorimetrically detecting amphetamine and methyamphetamine in drugs based on furyl probes. The furyl probes in the method are furan-indanone, furan-indene dicyanide and furan-indene cyanide respectively. Wherein before and after amphetamine or methyl amphetamine is added into the probe furan-indanone, the color of the solution is changed from faint yellow to rose red; before and after amphetamine or methyl amphetamine is added into the probe furan-indene dicyanide, the color of the solution is changed from brown yellow to blue; the color of the solution is changed from yellow to orange before and after amphetamine is added into the probe furan-indene cyanogen, and the color of the solution is changed from yellow to green before and after methylamphetamine is added into the probe furan-indene cyanogen. Rapid colorimetric distinguishing of single amphetamine or methyamphetamine and qualitative detection of a mixture of amphetamine and methyamphetamine are achieved. The method has no special limitation in use, can quickly complete qualitative detection without pretreatment of an object to be detected, is simple to operate, economical, practical, high in specificity and sensitivity, stable and repeatable in result, and can be practically applied and popularized.

Disclosed herein are 2-thioxothiazolidine-4-one derivatives, and pharmaceutical compositions thereof. The 2-thioxothiazolidine-4-one derivatives and pharmaceutical compositions thereof may be used to treat or prevent medical disorders such as, for example, Parkinson's disease, and disorders of dopamine homeostasis, such as for example, methamphetamine and cocaine addiction.

The invention relates to the technical field of drug detection, in particular to an environment drug detection and collection reagent and a use method thereof.The environment drug detection and collection reagent comprises 0.05%-5% of a preservative, 0.5%-10% of a scale inhibitor, 0.1%-5% of a surfactant and a pH regulator; the pH value of the drug detection and collection reagent in the environment is 6.5-8.5; the detection and collection reagent for the drugs in the environment is wide in application range, and can be suitable for rapid collection and detection of the drugs such as morphine, methamphetamine, ketamine, cocaine, cannabis sativa, ecaloin, etomidate and dextromethorphan. The drug detection and collection reagent can effectively reduce the detection threshold value of a high-sensitivity detection plate, further improves the sensitivity of drug detection and analysis, and is suitable for further popularization and application.

This invention belongs to the field of biomedicine and discloses for the first time the application of sinapic acid and its derivatives, methyl myrosate and ethyl myrosate, in the prevention and / or treatment of methamphetamine addiction withdrawal. By investigating the conditional position preference behavior of methamphetamine-addicted mice and mice treated with sinapic acid, methyl myrosate, and ethyl myrosate, the inventors demonstrated that sinapic acid and its derivatives, methyl myrosate and ethyl myrosate, can reduce dependence on and cravings for methamphetamine. Therefore, sinapic acid and its derivatives, methyl myrosate and ethyl myrosate, can serve as active ingredients in the preparation of addiction treatment drugs, providing a new option for the prevention and / or treatment of methamphetamine addiction and showing promising clinical application prospects.

This invention provides a method for constructing a donor-acceptor type perylene diimide-based porous conjugated polymer probe and detecting methamphetamine and amphetamine solutions. The method synthesizes donor-acceptor type perylene diimide-based porous conjugated polymer probes with different topologies by combining an electron acceptor perylene diimide derivative and an electron donor aggregation-induced emission fluorophore via a succinate coupling reaction. When used for the detection of methamphetamine and amphetamine, this system exhibits a clear ratiometric fluorescence response, with the fluorescence color gradually changing from yellow-green to orange and orange-red, demonstrating a significant ratiometric fluorescence response. It features fast response speed, high detection sensitivity, good selectivity, and no interference from other common structurally and property-similar substances, enabling the differentiation and identification of methamphetamine and amphetamine.

The present invention discloses a kind of 7-dehydrocholesterol-perylene diimide derivative and its preparation and application of fluorescent film, and utilizes the advantages such as the rigid structure and multiple chiral centers of 7-dehydrocholesterol to connect the conjugated fluorescent molecule with high fluorescence quantum yield, perylene anhydride, through a connecting arm. The synthesized fluorescent compound is used as a sensing element to prepare a fluorescent film, which can be used to detect a variety of banned drugs such as methamphetamines, and is applied to the field of banned drug detection. The present invention is simple to operate, and the reaction conditions are mild. The prepared fluorescent sensor film has high fluorescence quantum yield, good stability, low detection limit, long service life, and high detection sensitivity. It can be applied in sensors for detecting a variety of banned drugs such as methamphetamines. This type of fluorescent sensor film is installed in a portable fluorescence detector for supporting use to achieve rapid detection of banned drugs and improve the detection efficiency of banned drugs.

The application discloses a medicine for treating or preventing methamphetamine addiction and application, and discloses a new use of an ERK inhibitor. The application studies the application of the ERK inhibitor in drug addiction, studies the inhibiting effect of GDC-0994 on treating methamphetamine addiction through a methamphetamine addiction model (including a position preference model and a self-administration experiment model), finds that the ERK inhibitor GDC-0994 can significantly reduce the seeking and intake of methamphetamine of animals, that is, the ERK inhibitor GDC-0994 can antagonize the addiction of methamphetamine, and indicates that the GDC-0994 inhibiting ERK can effectively treat the methamphetamine addiction.

The invention discloses a method for detecting methamphetamine based on a Co-AD quantum dot molecular imprinting fluorescence sensor. The method comprises the following steps: step 1, preparing Co-AD quantum dots; step 2, synthesizing a Co-AD quantum dot molecularly imprinted fluorescence sensor; 3, drawing a standard working curve of fluorescence quenching intensity-methamphetamine concentration; 4, measuring the content of methamphetamine in the sample; the Co-AD quantum dot molecularly imprinted fluorescent sensor prepared by the method combines high selectivity, simplicity, convenience and rapidness of molecularly imprinted polymer and high sensitivity of fluorescence detection, can accurately and specifically recognize methamphetamine, and is effectively applied to field rapid detection of drugs, the linear detection range of the detection method to methamphetamine is 67-469nM, and the detection method has a wide application prospect. The detection limit is as low as 23nM.

The present invention belongs to the field of biomedicine, and discloses the application of eleutheroside B in the preparation of drugs for preventing and / or treating methamphetamine addiction withdrawal. The inventor evaluated the role of eleutheroside B in preventing and treating methamphetamine addiction by investigating the effects of eleutheroside B on methamphetamine-induced conditioned place preference and behavioral sensitization. It was experimentally confirmed that eleutheroside B could reverse methamphetamine-induced conditioned place preference and reduce methamphetamine-induced hyperlocomotor activity, and had an inhibitory effect on the expression of methamphetamine-induced behavioral sensitization in mice, indicating that eleutheroside B could effectively weaken the dependence and craving for methamphetamine, weaken the induced behavioral sensitization effect, and could be used for preventing and treating methamphetamine addiction. The present invention develops a new drug for drug rehabilitation with eleutheroside B as the active ingredient, provides an effective and safe option for the prevention and treatment of methamphetamine addiction, and has good clinical application prospects.

The invention discloses an application of cannabidiol in preparation of a methylamphetamine addiction memory intervention medicine. The research shows that the cannabidiol can slow down the formation of the methamphetamine addiction memory, the pharmacological mechanism of the cannabidiol in slowing down the methamphetamine addiction memory is explored, and the result shows that the cannabidiol can weaken the activation of a TRPV1 channel on hippocampus blotting cells and hinder the coding of the addiction memory blotting in mouse hippocampus; according to the invention, the pharmacological mechanism of cannabidiol in slowing down methamphetamine addiction memory is explored; and a new treatment strategy can be provided for drug rehabilitation treatment of methamphetamine addiction memory.

The invention discloses an antigen-coupled PVDF-PEI membrane type SERS sensor constructed based on a surface enhanced Raman scattering (SERS) technology, the antigen-coupled PVDF-PEI membrane type SERS sensor comprises two parts of a specific immune probe and an antigen-coupled PVDF-PEI composite membrane, and the preparation of the antigen-coupled PVDF-PEI membrane type SERS sensor comprises the following steps: synthesizing Au (at) 4-MBA (at) Ag NPs with a core-shell structure through gold nanoparticles (AuNPs), and coupling an METH antibody to obtain an SERS immune probe; meanwhile, a PVDF film is subjected to pretreatment, surface PEI modification and tannic acid modification to prepare a PVDF-PEI composite film, and then the PVDF-PEI composite film is coupled with an METH antigen (METH-BSA) to form the detection substrate. The prepared antigen-coupled PVDF-PEI membrane type SERS sensor can be used for ultra-trace detection of methylamphetamine (METH) and derivatives thereof in a liquid sample, has the advantages of high sensitivity, good anti-interference capability and the like, and has very huge popularization and application values.

This invention discloses a method for rapid quantitative analysis of methamphetamine based on portable near-infrared spectroscopy and PLS modeling, characterized by: (1) collecting near-infrared diffuse reflectance spectra of methamphetamine crystals and tablets using a portable near-infrared analyzer, and preprocessing the spectral data using the S-G method; (2) performing data analysis and modeling based on the PLS method to obtain a PLS regression model; (3) detecting the sample to be tested: collecting the near-infrared diffuse reflectance spectra of the sample to be tested, and then obtaining the methamphetamine content in the sample to be tested according to the model in step (2).

The invention relates to the technical field of biological medicines, in particular to application of N-acetylneuraminic acid in preparation of a medicine for treating methamphetamine addiction. The key effect of N-acetylneuraminic acid (Neu5Ac) in methamphetamine addiction treatment is found for the first time, the CPP score of a methamphetamine addiction mouse can be obviously reduced, it is proved that the N-acetylneuraminic acid (Neu5Ac) has a good treatment effect on methamphetamine addiction, and Neu5Ac can be subjected to endogenous synthesis and has the advantages of being good in biocompatibility and small in toxic and side effect.

The invention relates to the technical field of spectrum detection, in particular to a drug spectrum sealing detection device, which comprises a main shell, and can realize pure mechanical rapid switching of compensating plates aiming at spectrum interference generated by different sealing packaging materials when in use, so that the sealing performance of the drug spectrum sealing detection device is improved. The problem that spectrum signals of a sealing packaging material are overlapped with spectrum signals of drugs such as methamphetamine, ketamine and diacetylmorphine is effectively solved, interference signals are prevented from covering drug characteristic spectrum peaks, misjudgment and missed judgment of detection are prevented, the driving switching assembly is in linkage through components such as a gear column, a limiting rack and an abutting idler wheel, and the detection efficiency is improved. According to the invention, the signal acquisition function of the intelligent spectrum sensor is combined, so that the detection accuracy and reliability are greatly improved, the requirements of on-site fast detection and conventional detection are met, and the technical defect that an existing device is not provided with an effective spectrum interference compensation structure is overcome.

The invention discloses a nano drug-loading delivery system for treating methamphetamine addiction and a preparation method and a pharmaceutical preparation thereof, and belongs to the technical field of medical configuration products. According to the nano drug-loaded delivery system, exosome from HUVECs (human umbilical vein endothelial cells) engineered and modified by hypoxia pretreatment and transcription activator protein (TAT) is used as a nano carrier of cannabidiol CBD, and compared with a drug delivery mode of high-invasiveness intraventricular injection or high-dose intraperitoneal injection (40-100 mg / kg) in treatment of METH addiction at present, the nano drug-loaded delivery system has the advantages that the drug delivery efficiency is greatly improved; the nano drug-loading delivery system treats METH addiction in a nasal delivery mode, and the effective concentration of the nano drug-loading delivery system is only 2 mg / kg and is only 1 / 20 of the minimum effective concentration (40 mg / kg) of intraperitoneal injection CBD solution for treating METH addiction.

The application relates to a marker, a kit and an application for differentiating methamphetamine-induced psychosis from primary schizophrenia, and belongs to the technical field of biological medicine and judicial expertise. The application provides application of miRNA as a marker in preparation of a product for differentiating methamphetamine-induced psychosis from primary schizophrenia, wherein the miRNA comprises at least one of hsa-miR-11400, hsa-miR-1908-3p, hsa-miR-4433b-3p and nov-miR-chr20. The application takes nov-miR-chr20 as a forward specific marker of PS, and takes the other three miRNAs as forward indicating markers of MAP, effectively avoids false positive or false negative, improves the specificity and sensitivity of detection, ensures stability and repeatability, and solves the misdiagnosis problem caused by high overlap and similarity of MAP and PS.

Disclosed are pharmaceutical compositions and formulations of enantiomerically enriched or pure 3,4-methylenedioxymethamphetamine (MDMA) and methods for modulating aggression response behaviors that may be associated with a disorder and / or disease.

The invention provides an application of MCU (Microprogrammed Control Unit) in treating addictive diseases. By means of a conditional knockout dopamine system mouse model, it is observed that motonous nerve excitability caused by heroin, morphine and methamphetamine is remarkably reduced due to deficiency of MCU. In addition, behavioral experiments further prove that the MCU knockout significantly reduces the addiction desire of mice to heroin and methamphetamine. By applying MCU inhibitors, namely mitoxantrone (MTX) and Ru265, the inhibitors are found to be capable of remarkably inhibiting motor nerve excitability caused by heroin and reducing addiction and relapse behaviors of mice on heroin. Mechanism research reveals that MCU knockout inhibits dopamine release caused by opioids and methamphetamine in a nucleus septum (NAc) area, and it is indicated that MCU may serve as an effective target for treating addiction of multiple drugs. The invention provides a brand-new treatment strategy for inhibiting MCU as a clinical treatment for opioid (morphine) or drug (heroin) and methamphetamine addiction for the first time.

The application provides a composite fluorescent sensing material for detecting methamphetamine, and belongs to the technical fields of fluorescent sensing materials and drug detection. The composite fluorescent sensing material is obtained by reacting a precursor molecule R1-FR2-R3 with a metal salt compound. The precursor molecule R1-FR2-R3 is synthesized from an organic ligand capable of coordinating and cross-linking with metal ions, a fluorinated benzene ring containing two aldehyde groups, and a recognition molecule capable of selectively adsorbing MAs and producing fluorescence quenching. When a fluorescent sensing film prepared by using the composite fluorescent sensing material is used for detecting methamphetamine compounds, the fluorescent sensing film has excellent selectivity and sensitivity. The method for preparing the composite fluorescent sensing material in the application can control the morphology and size of the material, so that a material structure more conducive to enriching MAs molecules can be selected and prepared.

The invention discloses a preparation method of a bromine lead deuteride methylamine perovskite single crystal, and belongs to the technical field of crystal growth. The preparation method comprises the following steps: performing multiple deuteration on bromomethylamine, performing heavy water separation and recovery on a mixed solution containing bromomethylamine and heavy water generated after each deuteration, and synthesizing a bromine lead methylamine deuteride single crystal. Bromomethylamine and heavy water are subjected to multiple times of deuteration in a certain proportion to generate bromomethylamine deuteride, then bromomethylamine deuteride and lead bromide are subjected to inverse temperature crystallization in an organic solvent, and the bromolead deuteride methylamine perovskite single crystal is synthesized. The preparation method provided by the invention has the advantages that the synthesis process is efficient, safe and controllable, heavy water can be recycled, the synthesis cost is greatly reduced, and the stability of the synthesized bromine lead deuteride methylamine perovskite single crystal is greatly improved.

A composition of a salt or polymorph of the crystalline form of R-MDMA. A pharmaceutical composition of a salt or polymorph of the crystalline form of R-MDMA and a pharmaceutically acceptable excipient. A method of treating a medical condition of an individual by administering to the individual an effective amount of the composition of a salt or polymorph of the crystalline form of R-MDMA and treating the individual.

The present invention relates to the field of plant nutrition, and particularly to an optimized nitrogen fertilization strategy based on soil fumigation. The present invention provides a nitrogen fertilizer application strategy based on soil fumigation, comprising the following steps: applying nitrogen fertilizer after soil fumigation; the soil fumigant comprises one or more of chloropicrin, dazomet, methamphetamine, dimethyl disulfide, horseradish, and ethionol; the fumigant dosage is divided into a low dose of 20 to 40 kg / mu and a high dose of 40 to 80 kg / mu; the nitrogen fertilizer is a combination of ammonium nitrogen and nitrate nitrogen, with 1 / 8 of the nitrogen fertilizer's mass used as a base fertilizer, and the remaining nitrogen fertilizer is applied in four equal portions as topdressing; the total amount of the base fertilizer and topdressing is 32 to 40 kg / mu; the mass ratio of ammonium nitrogen fertilizer to nitrate nitrogen fertilizer in the nitrogen fertilizer is 50 to 100:0 to 50; and the mass of ammonium nitrogen fertilizer and nitrate nitrogen fertilizer in the nitrogen fertilizer is unequal. Compared with conventional nitrogen application, this method can significantly increase crop yields.